Tositumomab
PharmacokineticsPharmacokinetics
| Anti-CD20 Monoclonal Antibody Pharmacokinetics | ||||
|---|---|---|---|---|
| Parameter | Tositumomab | Ofatumumab | Rituximab | Ibritumomab |
| Tmax (hr) | Tositumomab | Ofatumumab | Rituximab | Ibritumomab |
| Cmax (ng/ml) | Tositumomab | Ofatumumab | Rituximab | Ibritumomab |
| Bioavailability (%) | Tositumomab | Ofatumumab | Rituximab | Ibritumomab |
| Protein Binding (%) | Tositumomab | Ofatumumab | Rituximab | Ibritumomab |
| T1/2 (hr) | Tositumomab | Ofatumumab | Rituximab | Ibritumomab |
| AUC (ng/ml/hr) | Tositumomab | Ofatumumab | Rituximab | Ibritumomab |
| Clearance (L/h) | Tositumomab | Ofatumumab | Rituximab | Ibritumomab |
| IC50 (nM) | Tositumomab | Ofatumumab | Rituximab | Ibritumomab |
| Dosage (mg) | Tositumomab | Ofatumumab | Rituximab | Ibritumomab |
| Metabolism | Tositumomab | Ofatumumab | Rituximab | Ibritumomab |